Our NASH/MASH Treatment Focus

Madrigal’s first therapy is designed to target the underlying causes of NASH in the liver.

NASH Patients - Madrigal Pharmaceuticals

Our therapy is designed to target the underlying cause of NASH in the liver.

Our novel therapeutic emerged from a research program examining the role of the thyroid hormone receptor (THR) β pathway in liver health.

Madrigal scientists and researchers, working with leading experts in hepatology, have been studying the therapy’s ability to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis.

Based on Phase 3 results reported to date, the U.S. FDA granted accelerated approval for our therapy for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

Madrigal is the leading biopharmaceutical company studying the therapeutic potential of THR-β agonism to improve liver health for patients with NASH.